Health Care · Pharmaceutical Preparations

AMLX Amylyx Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 165855197 filings
Russell 2000

AMLX at a glance

Amylyx Pharmaceuticals, Inc. (AMLX, SEC CIK 1658551) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Amylyx Pharmaceuticals, Inc. (AMLX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $144.7 million. Diluted EPS was -$1.53.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Amylyx Pharmaceuticals, Inc. (AMLX) shares worth $1.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by FRATES JAMES M on November 10, 2026 of 7,200 shares at $30.97 per share.
  • In the last 90 days, AMLX insiders reported 0 open-market purchases ($0) and 19 open-market sales ($11.0M) on Form 4, a net sale of $11.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
−100.0% vs prior year
Insiders · 90 days
0 buys · 19 sells
Net −$11.0M
13F holders
28 funds
$1.2B · +2 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Clinical-stage pharma developing novel therapies for endocrine and neurodegenerative diseases with mechanistic rationale and biomarker-driven pipeline
  • New products: Advanced Phase 3 trial for avexitide in PBH; initiated Phase 1 trial for AMX0114 in ALS and selected AMX0318 for long-acting GLP-1 antagonist development
  • Strategic shift: Acquired avexitide patent portfolio in July 2024, expanding IP estate significantly; emphasis on broader rare disease indications including Wolfram syndrome and ALS
  • Quantitative metric: Patent estate grew to 23 U.S. and 257 foreign issued patents plus 130+ pending applications as of Dec 31, 2025; 75 participants enrolled in Phase 3 LUCIDITY trial
  • Noteworthy fact: Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome showing sustained pancreatic beta cell function improvement through 48 weeks

Risk Factors

  • Cybersecurity risk oversight by board and executive team with escalation for material incidents to audit committee
  • Dependence on Senior Director of ISGA with CISSP and 20+ years experience for daily information security strategy
  • Reliance on external vendors for managed network support and security operations creating supply chain cybersecurity risk

Management Discussion & Analysis

  • Revenue $0 in 2025 vs $87.4M in 2024, 100% decline due to discontinuation of RELYVRIO®/ALBRIOZA™ product sales
  • Operating loss $153.3M in 2025 vs $314.7M in 2024, a 51% improvement; R&D expenses down 13% to $90.4M; SG&A down 45% to $62.9M
  • Best performing segment: Avexitide R&D up 771% to $24.1M; worst: AMX0035-ALS R&D down 95% to $1.8M
  • Cash from financing $257.0M in 2025 led by two equity offerings raising approx. $256.2M net; operating cash burn $123.3M; cash & equivalents $317.0M at year-end
  • Management expects R&D and G&A expenses to increase as clinical programs advance; key risks include clinical trial outcomes, regulatory approvals, and capital access

AI summary of the AMLX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • No quarterly revenue, as Amylyx remained pre-commercial
  • Net loss $45.5M vs $34.4M YoY, operating margin not applicable
  • R&D $28.4M vs $19.9M, led by avexitide spending of $10.7M
  • Cash, equivalents and marketable securities $768.1M, boosted by $544.6M equity proceeds
  • Avexitide NDA submission targeted by end-2026, potential commercial launch in 2027 if approved

Risk Factors

  • Newly added regulatory risk: 2026 FDA draft guidance and policy reversals may make single-trial approval standards uncertain
  • Most materially updated regulatory risk: FDA leadership changes and personnel reductions could delay guidance, reviews, and approvals
  • Operational risk: rising GLP-1 demand could constrain peptide-manufacturing capacity and increase avexitide supply costs
  • Competitive risk: novel obesity treatments could reduce bariatric surgery and shrink the PBH patient population
  • Financial risk: accumulated deficit reached $881.6 million, with no committed source of additional capital

AI summary of the AMLX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release issued November 5, 2026

Item EX-99.1: Item EX-99.1

  • Phase 3 LUCIDITY met its primary endpoint, reducing Level 2 and 3 hypoglycemic events 55% versus placebo, with p=0.000003
  • Avexitide NDA submission remains targeted for end-2026, supporting a potential 2027 launch if FDA-approved
Filed Sep 8, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Dual-source manufacturing secured for avexitide commercial supply, contingent on regulatory approval
  • Bachem agreement requires minimum annual purchases beginning 2028, creating future volume commitments
Filed Aug 20, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Amylyx raising $500.2 million gross through 14.09 million shares at $35.50 each
  • Underwriters hold a 30-day option for 2.1135 million additional shares

AI summaries of AMLX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AMLX

Don't miss the next AMLX filing

  • Alerts as it files. A push when AMLX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AMLX, by share count.
  • Ask anything. An AI agent that reads every AMLX filing and answers with sources.

AMLX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
FRATES JAMES MMNov 10, 2026-
FRATES JAMES MSellNov 10, 2026$30.97
FRATES JAMES MMNov 10, 2026$6.88
FRATES JAMES MSellNov 10, 2026$30.32
FRATES JAMES MMNov 9, 2026-
FRATES JAMES MSellNov 9, 2026$30.11
FRATES JAMES MMNov 9, 2026$6.88
FRATES JAMES MSellNov 9, 2026$29.39

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$87.4M$0
Operating Income--$314.7M-$153.3M
Net Income$49.3M-$301.7M-$144.7M
Op. Margin--360.2%-
Net Margin--345.4%-
Balance Sheet
Total Assets-$193.6M$332.6M
Equity$433.4M$164.8M$305.3M
ROE11.4%-183.1%-47.4%
Per Share
EPS$0.70$-4.43$-1.53
Cash Flow
Operating CF--$167.6M-$123.3M
CapEx$1.2M$157K$138K

Source: XBRL data in Amylyx Pharmaceuticals, Inc. (AMLX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AMLX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AMLX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$1.18B
Q2 202626$875.6M
Q1 202625$618.2M
Q4 202524$529.9M
Q3 202525$457.1M
Q2 202526$144.4M
Q1 202521$59.0M
Q4 202417$31.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 192 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AMLX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 7, 2026--
4Sep 14, 2026--
4Sep 14, 2026--
4Sep 14, 2026--
4Sep 14, 2026--
4Sep 14, 2026--
8-KSep 8, 2026Analysis-
4Sep 2, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
8-KAug 20, 2026Analysis-
4Aug 20, 2026--
4Aug 20, 2026--
8-KAug 18, 2026Analysis-
8-KAug 18, 2026Analysis-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 13, 2026--
4Jun 8, 2026-

Related Health Care companies

All Health Care →

AMLX SEC filings: frequently asked questions

Are AMLX insiders buying or selling?

In the last 90 days, Amylyx Pharmaceuticals, Inc. (AMLX) officers, directors and 10% owners reported no open-market purchases and 19 open-market sales worth $11.0 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold AMLX stock?

As of September 30, 2026, the largest Amylyx Pharmaceuticals, Inc. (AMLX) holders among the 13F filers tracked by SignalX were BlackRock ($301.7 million), Vanguard Capital Management LLC ($147.8 million), Franklin Resources ($115.6 million), Goldman Sachs Group ($104.4 million), JPMorgan Chase & Co ($100.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AMLX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Amylyx Pharmaceuticals, Inc. (AMLX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $144.7 million. Diluted EPS was -$1.53. The figures come from the XBRL data in the 10-K.

What are the main risks in AMLX's latest 10-K?

In the 10-K filed March 3, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) flagged: Cybersecurity risk oversight by board and executive team with escalation for material incidents to audit committee. Dependence on Senior Director of ISGA with CISSP and 20+ years experience for daily information security strategy. (AI summary of the Risk Factors section.)

What did AMLX report in its latest 8-K?

Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest AMLX SEC filings?

Amylyx Pharmaceuticals, Inc. (AMLX) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 12, 2026.

What is AMLX's SEC CIK number?

Amylyx Pharmaceuticals, Inc. (AMLX)'s SEC Central Index Key (CIK) is 1658551. EDGAR lists every AMLX filing under that number.

Ask anything about AMLX

The research agent reads AMLX's filings, financials, insider trades and 13F holders, then answers with sources.